RE: Analysts Targets $22.75 Average....125% Gain
.....Adding Cannacord to the mix of Targets brings the Average to $22.75...from where we sit right now that will be a 125% Gain. With the timelines being adjusted for TT223 just lately from a few of the Analysts and current updates after the Q2 we can more than likely look forward to Price Target adjustments upwards to account for the progress of the Clinicals. Next Q will bring the TT223 SA Phasell into play as well.
We'll just Average their Targets. Every one of them has at least a BUY or OUTPERFORM or the like. If anyone has the Octogon OR the Paradigm Target numbers let us in on the amount........TIA
Analyst--------Target
Cannacord------$18.40
Laurentian-----$23.00
GMP------------$25.00
Cormark--------$18.50
Leerink Swann--$24.00
Versant--------$17.00
NCB------------$34.50
Cowen & Co.----$19.31
RBC C.M.-------$25.00
Octogon--------$??.??
Paradigm-------$??.??
-------------------------
Average is $22.75....Thats a 127% Gain from here. Not too shabby.